TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19156474

Group type: EXPERIMENTAL
Intervention: Cerebellar conditioning TMS
Number of subjects: 17

Group type: COMPARATOR
Intervention: Test stimulus (TS) on contralateral motor cortex
Number of subjects: 17
Study: 17342995

Group type: EXPERIMENTAL
Intervention: Tangweikang (TWK)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Domperidone (Control)
Number of subjects: 90

Group type: COMPARATOR
Intervention: No additional drug (Blank group)
Number of subjects: 90
Study: 15112871

Group type: EXPERIMENTAL
Intervention: Cefazolin 1 gr. i.v. preoperative and every 8 hrs. during the first day (3 doses) followed by ciprofloxacin 250 mg. oral every 12 hrs until catheter removal.
Number of subjects: 90

Group type: COMPARATOR
Intervention: Cefazolin 1 gr. i.v. preoperative and at 8 hrs postoperative (2 doses) followed by nitrofurantoin 100 mg. oral every night until catheter removal.
Number of subjects: 90
Study: 11487421

Group type: EXPERIMENTAL
Intervention: Attrition prevention intervention
Number of subjects: 654

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 654
Study: 9684126

Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg once daily)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Ranitidine (150 mg twice daily)
Number of subjects: 223
Study: 7546090

Group type: EXPERIMENTAL
Intervention: Photo method (computer digitization of color slide photographs)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Tracing method (acetate tracings)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Both methods (photo and tracing)
Number of subjects: 450
Study: 2460414

Group type: EXPERIMENTAL
Intervention: Tunable dye laser at 577 nm
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Tunable dye laser at 590 nm
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Tunable dye laser at 620 nm
Number of subjects: 27
Study: 31147190

Group type: EXPERIMENTAL
Intervention: Paravertebral block
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Intercostal nerve block
Number of subjects: 105

Group type: COMPARATOR
Intervention: General anaesthesia (control group)
Number of subjects: 105
Study: 31005596

Group type: EXPERIMENTAL
Intervention: 20 mg desmetramadol
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: 50 mg tramadol
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: CYP inhibition with tramadol
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: CYP inhibition with desmetramadol
Number of subjects: 103
Study: 29092739

Group type: EXPERIMENTAL
Intervention: Oral iron (200 mg elemental iron/day)
Number of subjects: 308
Study: 25280604

Group type: EXPERIMENTAL
Intervention: Exercise therapy
Number of subjects: 159
Study: 23456922

Group type: EXPERIMENTAL
Intervention: HR-pQCT PR model
Number of subjects: 60
Study: 22066459

Group type: EXPERIMENTAL
Intervention: Shenmai injection (0.6 mL x kg(‐1) and physiological saline 100 mL)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Normal saline (equal volume to Shenmai injection)
Number of subjects: 26
Study: 19628730

Group type: EXPERIMENTAL
Intervention: 1 spray of 1.7% estradiol transdermal spray (1.53 mg/spray) once daily for 14 days
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 2 sprays of 1.7% estradiol transdermal spray (1.53 mg/spray) once daily for 14 days
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 3 sprays of 1.7% estradiol transdermal spray (1.53 mg/spray) once daily for 14 days
Number of subjects: 72
Study: 17019520

Group type: EXPERIMENTAL
Intervention: Maxmarvil (calcitriol 0.5 mug and alendronate 5 mg)
Number of subjects: 199

Group type: COMPARATOR
Intervention: Alfacalcidol
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Maxmarvil
Number of subjects: 199
Study: 12952272

Group type: EXPERIMENTAL
Intervention: Inflation of the oesophageal balloon
Number of subjects: 14

Group type: COMPARATOR
Intervention: Deflation of the oesophageal balloon
Number of subjects: 14
Study: 10949718

Group type: EXPERIMENTAL
Intervention: Actarit treatment for 24 weeks in group I (stages I and II)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Actarit treatment for 24 weeks in group II (stages III and IV)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Actarit treatment in group I
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Actarit treatment in group II
Number of subjects: 37
Study: 8767154

Group type: EXPERIMENTAL
Intervention: Indobufen
Number of subjects: 980

Group type: COMPARATOR
Intervention: Heparin calcine
Number of subjects: 980

Group type: COMPARATOR
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 980
Study: 1351053

Group type: EXPERIMENTAL
Intervention: Oral repeat‐action albuterol sulfate (Proventil Repetabs), 4 mg in the morning and 4‐16 mg at bedtime
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study: 4096741

Group type: EXPERIMENTAL
Intervention: 20 mg nifedipine retard-tablet (Pidilat retard)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 20 mg nifedipine retard-tablet (marketed formulation)
Number of subjects: 12
Study: 31372674

Group type: EXPERIMENTAL
Intervention: Bovine aortic arch variant in embolic stroke patients (25.7%)
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: Bovine arch subtype B in embolic stroke patients (10.5%)
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: Bovine arch subtype A
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: Other commonly observed variant branching patterns of the aortic arch
Number of subjects: 474
Study: 29577519

Group type: EXPERIMENTAL
Intervention: Ethosuximide (ETX)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Inactive control (IC)
Number of subjects: 114
Study: 27165014

Group type: EXPERIMENTAL
Intervention: Melatonin 3 mg
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Amitriptyline 25 mg
Number of subjects: 196

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 196
Study: 24989685

Group type: EXPERIMENTAL
Intervention: Gadolinium injection (0.2 mmol/kg)
Number of subjects: 28
Study: 22281833

Group type: EXPERIMENTAL
Intervention: Fresh RBC transfusion (≤5 days of storage)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard issue RBC transfusion (26.5 days of storage)
Number of subjects: 100
Study: 21061888

Group type: EXPERIMENTAL
Intervention: Brückner test
Number of subjects: 2371

Group type: EXPERIMENTAL
Intervention: Brückner test with room lights off
Number of subjects: 2371

Group type: COMPARATOR
Intervention: Conventional vision testing
Number of subjects: 2371
Study: 19026803

Group type: EXPERIMENTAL
Intervention: Polytetrafluoroethylene neochordae (loops)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Leaflet resection
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 129
Study: 16446745

Group type: EXPERIMENTAL
Intervention: Diet plus low‐intensity exercise
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Diet plus high‐intensity exercise
Number of subjects: 45

Group type: COMPARATOR
Intervention: Diet only
Number of subjects: 45
Study: 12652385

Group type: EXPERIMENTAL
Intervention: Influenza vaccine
Number of subjects: 1248

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 1248
Study: 10463623

Group type: EXPERIMENTAL
Intervention: Breakfast cereal
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Caffeinated coffee
Number of subjects: 144

Group type: COMPARATOR
Intervention: No breakfast (control)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Decaffeinated coffee (control)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Breakfast cereal (control)
Number of subjects: 144
Study: 7756796

Group type: EXPERIMENTAL
Intervention: Continuous negative extrathoracic pressure ventilation
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Intermittent positive pressure ventilation
Number of subjects: 29
Study: 2334616

Group type: EXPERIMENTAL
Intervention: Bupivacaine 2 mg kg‐1
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Bupivacaine 2 mg kg‐1 with adrenaline 1:200,000
Number of subjects: 11
Study: 484890

Group type: EXPERIMENTAL
Intervention: Chloroprocaine, 3%
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Bupivacaine, 0.5%
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Chloroprocaine (1.5%) and Bupivacaine (0.375%) mixture
Number of subjects: 49
Study: 30536218

Group type: EXPERIMENTAL
Intervention: Educational curriculum focused on the medical needs of TAY with autism; Intervention group (n=6)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Waitlist control group (WLC); Control group (n=8)
Number of subjects: 14
Study: 28535777

Group type: EXPERIMENTAL
Intervention: SFA-reduced, MUFA-enriched dairy product
Number of subjects: 54
Study: 26145190

Group type: EXPERIMENTAL
Intervention: Topical application of tranexamic acid (TXA) 3 g plus diluted epinephrine (DEP) 0.25 mg
Number of subjects: 107

Group type: COMPARATOR
Intervention: Topical application of tranexamic acid (TXA) 3 g alone
Number of subjects: 107
Study: 23307164

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.25 μg/kg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 μg/kg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline 10 ml
Number of subjects: 60
Study: 21930354

Group type: EXPERIMENTAL
Intervention: Transdermal testosterone spray for 26 weeks
Number of subjects: 9
Study: 18281145

Group type: EXPERIMENTAL
Intervention: 10mg vardenafil twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 17069951

Group type: EXPERIMENTAL
Intervention: St. John Ambulance online 'crash course' (theoretical course)
Number of subjects: 23

Group type: COMPARATOR
Intervention: No first aid training (control group)
Number of subjects: 23
Study: 12671882

Group type: EXPERIMENTAL
Intervention: Colonoscopy with chromoendoscopy (CE) using 0.1% methylene blue
Number of subjects: 165

Group type: COMPARATOR
Intervention: Conventional colonoscopy
Number of subjects: 165
Study: 11525337

Group type: EXPERIMENTAL
Intervention: True Acupuncture (TA)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo Needle Application (PA)
Number of subjects: 13
Study: 9565508

Group type: EXPERIMENTAL
Intervention: Balloon pulmonary valvuloplasty (BPV)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control group (no prior BPV)
Number of subjects: 9
Study: 7983580

Group type: EXPERIMENTAL
Intervention: Complementarity defined by Carson's model
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Complementarity defined by Kiesler's model
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Complementarity defined by Wiggins's model
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Behavioral ratings considering base rates
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Friendly antecedent behavior
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Quadrant behavior
Number of subjects: 80
Study: 2691477

Group type: EXPERIMENTAL
Intervention: Amoxycillin/clavulanate (iv 100 mg/kg/day followed by oral 50 mg/kg/day)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Benzylpenicillin (100,000 IU/kg/day) + netilmicin (5 mg/kg/day) + metronidazole (30 mg/kg/day) (iv followed by oral metronidazole 30 mg/kg/day)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 64
Study: 30802200

Group type: EXPERIMENTAL
Intervention: Ertugliflozin 2.5 mg BID
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Ertugliflozin 7.5 mg BID
Number of subjects: 50
Study: 396660

Group type: EXPERIMENTAL
Intervention: i.v. pirenzepine infusion (16 mg plus 2 mg/h for 2 hours)
Number of subjects: 19

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 19
Study: 31738778

Group type: EXPERIMENTAL
Intervention: Nyström method for approximating leading eigenvalues and eigenvectors in network-based analysis of complex vortical flows.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quasi-uniform column sampling
Number of subjects: 0

Group type: COMPARATOR
Intervention: Uniform column sampling
Number of subjects: 0
Study: 29619965

Group type: EXPERIMENTAL
Intervention: HIV-infected women receiving curative chemoradiation therapy (CRT)
Number of subjects: 143

Group type: COMPARATOR
Intervention: HIV-uninfected women receiving curative chemoradiation therapy (CRT)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: HIV-infected women receiving curative CRT
Number of subjects: 143

Group type: COMPARATOR
Intervention: HIV-uninfected women receiving curative CRT
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Factors associated with better 2-year OS
Number of subjects: 143
Study: 26777101

Group type: EXPERIMENTAL
Intervention: Video education plus verbal discussion
Number of subjects: 32

Group type: COMPARATOR
Intervention: Standard verbal discussion alone (control)
Number of subjects: 32
Study: 24720679

Group type: EXPERIMENTAL
Intervention: ABT‐450/r-ombitasvir and dasabuvir with ribavirin (150 mg of ABT‐450, 100 mg of ritonavir, 25 mg of ombitasvir, 250 mg dasabuvir twice daily, and 1000 or 1200 mg ribavirin daily)
Number of subjects: 394

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 394

Group type: EXPERIMENTAL
Intervention: ABT‐450/r-ombitasvir and dasabuvir with ribavirin
Number of subjects: 394
Study: 22948032

Group type: EXPERIMENTAL
Intervention: Monovo® Cream (new formulation of mometasone furoate with 33% water content)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Ecural® Fettcreme (commercially available fatty cream of mometasone furoate)
Number of subjects: 20
Study: 19399203

Group type: EXPERIMENTAL
Intervention: Externally generated feedback
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Self-generated feedback
Number of subjects: 26

Group type: COMPARATOR
Intervention: No feedback
Number of subjects: 26
Study: 17469882

Group type: EXPERIMENTAL
Intervention: Psychotherapy
Number of subjects: 153

Group type: COMPARATOR
Intervention: Medication
Number of subjects: 153
Study: 15253174

Group type: EXPERIMENTAL
Intervention: Interactive multimedia training program on breast self-examination using a breast model and computer guided feedback on accuracy of lump detection
Number of subjects: 58

Group type: COMPARATOR
Intervention: National Cancer Institute pamphlet on breast self-examination and breast lumps
Number of subjects: 58
Study: 12194635

Group type: EXPERIMENTAL
Intervention: Prednisone (40 mg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 9619531

Group type: EXPERIMENTAL
Intervention: Alpha‐methyl‐para‐tyrosine (AMPT), 5 x 1 g doses over 26 hours
Number of subjects: 10

Group type: COMPARATOR
Intervention: Promethazine (active placebo), 5 x 50 mg doses over 26 hours
Number of subjects: 10
Study: 7663867

Group type: EXPERIMENTAL
Intervention: PCA morphine plus tenoxicam (20 mg, i.v.)
Number of subjects: 41

Group type: COMPARATOR
Intervention: PCA morphine only
Number of subjects: 41
Study: 2540056

Group type: EXPERIMENTAL
Intervention: Sclerotherapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control
Number of subjects: 50
Study: 1261168

Group type: EXPERIMENTAL
Intervention: Azidomorphine
Number of subjects: 0
Study: 31502897

Group type: EXPERIMENTAL
Intervention: Home-based, cognitive behavioral programme (n=194)
Number of subjects: 389

Group type: COMPARATOR
Intervention: Usual care (n=195)
Number of subjects: 389
Study: 31319484

Group type: EXPERIMENTAL
Intervention: I2 (5 mg/day) before surgery for 7-35 days
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: FEC/TE + I2 after surgery for 170 days
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: I2 supplementation before and after surgery
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (colored water)
Number of subjects: 60

Group type: COMPARATOR
Intervention: FEC/TE
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: FEC/TE + I2 after surgery
Number of subjects: 60
Study: 27779896

Group type: EXPERIMENTAL
Intervention: Early neuromuscular blockade
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group with sedation
Number of subjects: 0
Study: 25597558

Group type: EXPERIMENTAL
Intervention: Multicomponent quality improvement program (Assessing Care of Vulnerable Elders Practice Redesign for Improved Medical Care for Elders)
Number of subjects: 1791

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1791
Study: 23984806

Group type: EXPERIMENTAL
Intervention: Canrenone 50 mg/day for 3 months, then 50 mg b.i.d. until the end of the study
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Canrenone
Number of subjects: 145
Study: 21878204

Group type: EXPERIMENTAL
Intervention: Burst-type TENS (pulse width, 200 μs; frequency, 100 Hz; burst frequency, 2 Hz) stimulation over the upper trapezius for 10 minutes
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Burst-type TENS stimulation
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo group (sham-TENS application over the upper trapezius for 10 minutes)
Number of subjects: 76
Study: 18703241

Group type: EXPERIMENTAL
Intervention: HeartOp Programme (cognitive-behavioural intervention)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Routine nurse counselling
Number of subjects: 204
Study: 17092457

Group type: EXPERIMENTAL
Intervention: Pediatric constraint‐induced therapy involving constraint of the functional upper extremity and intensive therapy with the hemiparetic upper extremity
Number of subjects: 18

Group type: COMPARATOR
Intervention: Conventional physical and occupational therapy
Number of subjects: 18
Study: 15289633

Group type: EXPERIMENTAL
Intervention: Local indigenous health workers using registers, recall and reminder systems, and basic diabetes care plans, supported by a specialist outreach service.
Number of subjects: 921
Study: 11275026

Group type: EXPERIMENTAL
Intervention: Estrogen therapy
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 9303287

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Eltanolone
Number of subjects: 67
Study: 8408933

Group type: EXPERIMENTAL
Intervention: Intravenous salbutamol (10 micrograms/kg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol (100 micrograms, twice)
Number of subjects: 8
Study: 2951814

Group type: EXPERIMENTAL
Intervention: Duovent
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30760195

Group type: EXPERIMENTAL
Intervention: ω‐3 fatty acids
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: nano‐curcumin
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Combination of ω‐3 fatty acids and nano‐curcumin
Number of subjects: 74
Study: 28371481

Group type: EXPERIMENTAL
Intervention: Brief Fear of Movement (BFOM) measure
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: KOOS ADL
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: PHQ-8
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Self-efficacy for exercise (SEE)
Number of subjects: 350
Study: 25136856

Group type: EXPERIMENTAL
Intervention: Ambient fine particulate matter (PM2.5) and ozone exposure
Number of subjects: 1218

Group type: EXPERIMENTAL
Intervention: Mean PM2.5 exposure
Number of subjects: 1218

Group type: EXPERIMENTAL
Intervention: Lagged exposures to air pollutants
Number of subjects: 1218

Group type: EXPERIMENTAL
Intervention: Low levels of ambient air pollutants
Number of subjects: 1218
Study: 23339313

Group type: EXPERIMENTAL
Intervention: Psychotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medication
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 21047922

Group type: EXPERIMENTAL
Intervention: Intralipid/heparin infusion with 1 mU/min · kg euglycemic insulin clamp
Number of subjects: 22

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 22
Study: 18496366

Group type: EXPERIMENTAL
Intervention: Insulin-mediated euglycemia (mean blood glucose, 5.8 +/- 0.4 mmol/L)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Moderate hyperglycemia (mean blood glucose, 9.6 +/- 0.6 mmol/L)
Number of subjects: 0
Study: 17042842

Group type: EXPERIMENTAL
Intervention: Intravenous granisetron 1 mg
Number of subjects: 960

Group type: EXPERIMENTAL
Intervention: Cyclizine 50 mg
Number of subjects: 960

Group type: EXPERIMENTAL
Intervention: Both granisetron and cyclizine
Number of subjects: 960
Study: 14667179

Group type: EXPERIMENTAL
Intervention: Rapidly hydrolysed starch (R)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Slowly hydrolysed starch (S)
Number of subjects: 21
Study: 11129548

Group type: EXPERIMENTAL
Intervention: Spironolactone 50 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Spironolactone 50 mg plus dexamethasone 0.5 mg (then 0.25 mg)
Number of subjects: 40
Study: 9090948

Group type: EXPERIMENTAL
Intervention: Isoflurane/N2O/sufentanil (group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Propofol/N2O/sufentanil (group B)
Number of subjects: 40
Study: 1874237

Group type: EXPERIMENTAL
Intervention: Local vibration at 60 Hz and an acceleration of 50 m·s‐2 for 5 minutes
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Noise at 100 dB(A) for 5 minutes
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Combined exposure to local vibration at 60 Hz and noise at 100 dB(A)
Number of subjects: 5
Study: 6846346

Group type: EXPERIMENTAL
Intervention: Training manual for pharmacists
Number of subjects: 35
Study: 31573984

Group type: EXPERIMENTAL
Intervention: Transanal total mesorectal excision (TaTME)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Laparoscopic approach
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Competency Assessment Tool (CAT)
Number of subjects: 101
Study: 28539093

Group type: EXPERIMENTAL
Intervention: Domestic violence services
Number of subjects: 4868

Group type: EXPERIMENTAL
Intervention: Increased levels of family engagement
Number of subjects: 4868

Group type: COMPARATOR
Intervention: CPS response pathway (investigation or assessment)
Number of subjects: 4868

Group type: COMPARATOR
Intervention: Service duration, intensity, and breadth
Number of subjects: 4868

Group type: EXPERIMENTAL
Intervention: Caseworker ratings of service-need match
Number of subjects: 4868
Study: 24630685

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZA) 4mg intravenously every 3 months for ≤4 years
Number of subjects: 1393

Group type: COMPARATOR
Intervention: Control group (standard PCa therapy alone)
Number of subjects: 1393

Group type: EXPERIMENTAL
Intervention: Zoledronic acid (ZA)
Number of subjects: 1393
Study: 22908852

Group type: EXPERIMENTAL
Intervention: Razor
Number of subjects: 215

Group type: COMPARATOR
Intervention: Clippers
Number of subjects: 215